Sumant Kulkarni

“ServoMed is developing nephlomapy mode for dementia with Lewy bodies. Dementia with Lewy bodies has significant unmet need. It's the second largest dementia, and it's unfortunately not addressed as much as Alzheimer's disease.”

“What exactly could you do to strengthen your, I guess, the request for the examination? Is there anything new you can file in terms of the real-world data that you've generated?”

“Grafman, thanks for taking your questions. I have two, one on rembepancerin and one on peak sales potential. So it looks like Bristol's enrollment for ADEPT or for Cobenphine ADP is going somewhat slower than that company initially expected.”

“First, how do you expect competitive and legal dynamics on psilocybin to play out, given the USUNA Institute also has a national priority voucher for its product and could already have its phase 3 data in-house for major depressive disorder.”

“I know you mentioned a couple of times today that you're running two phase three trials for ACP204 in Alzheimer's disease psychosis, but what does the FDA's recent publication of its official position on needing one robust pivotal trial plus confirmatory evidence mean for ACP204 in ADP and Lewy body dementia…”